Neuland Laboratories Ltd
NSE: NEULANDLAB BSE: 524558
₹19955
-245 (1.21%)
Fri, 23 Oct 2026, 03:57 am
Market Cap (in Cr)25916.82
PE Ratio51.43
Dividend0.17
Health Technology
Pharmaceuticals: Major
24.5KNeuland Laboratories Ltd Company History
1984
- Neuland Laboratories Limited was incorporated as a private limited company.
1986
- The company commenced operations at its plant at Bonthapally Village, Medak District, Andhra Pradesh.
1988
- Neuland Drugs & Pharmaceuticals Private Limited was incorporated.
1990
- The company expanded its installed capacity for salbutamol sulphate and its intermediates to 9 tpa.
1992
- The company entered into an agreement with Indian Institute of Chemical Technology for process know-how for the manufacture of Ketorolac Tromethamine and Enalapril Maleate on December 2nd.
1993
- The company completed a project for the manufacture of terbutaline sulphate, labetalol hydrochloride, and expanded the capacity of salbutamol sulphate to 18 tpa.
- Neuland Drugs & Pharmaceuticals Private Limited was merged with Neuland Laboratories Limited as per the Scheme of Amalgamation approved by the High Court of Andhra Pradesh.
1994
- The company completed a project for further diversifying its bulk drug manufacture and set up a new plant at I.D.A. Pashamylaram, Medak district, Andhra Pradesh.
- Commercial production commenced in October 1994.
- The company's equity issue of Rs.870 lacs was oversubscribed 70 times and the shares are listed on the Hyderabad and Bombay Stock Exchanges.
2009
- Ms. Deepika Gupta joined as Company Secretary and compliance officer of the company.
2012
- Neuland Laboratories Ltd issued rights in the ratio of 5:12.
- The registered office of the company was shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034.
2013
- The board recommended a dividend of Rs. 1.20 per share of a face value of Rs. 10 each.
- Neuland Labs received the 2013 CMO Leadership Award for Regulatory Excellence.
2014
- Neuland Labs inaugurated a new manufacturing facility constructed for its collaboration with Mitsubishi Healthcare Unit API Corporation.
- The board recommended a dividend of 30% at Rs. 3 per equity share on a face value of Rs. 10 each.
- Neuland Laboratories announced rights in the ratio of 4:25.
2016
- The company entered into a Joint Development Agreement with Phoenix Embassy Techno Zone Private Limited.
2017
- Neuland Labs completed the acquisition of an API plant.
